Colon cancer will affect approximately 140,000 persons and kill an estimated
55,000 people in 1997, making colon cancer the second deadliest cancer
in the United States. Hereditary nonpoly-posis colon cancer (HNPCC) accounts
for approximately 3% to 10% of colon cancers.
This autosomal dominant condition is characterized by an earlier age
of onset of colon cancer (in the 40s versus about age 65 for sporadic colon
cancer), a tendency for multiple tumors to form either simultaneously or
over time, and a tendency for tumors to occur proximal to the splenic flexure.
The pathology of the tumors is more likely to be mucinous and poorly
differentiated, but in contrast to this histologic grade, which would connote
a more aggressive tumor, HNPCC colon cancers have a better clinical outcome
than sporadic tumors matched for stage. [This will be discussed by Dr.
Risto Sankila of the Finnish Cancer Registry in the next article in this
In addition, there is an increased incidence of certain noncolonic tumors
in some HNPCC families, including those of the female reproductive tract,
stomach, and urinary tract.
Criteria for Studies of HNPCC
In 1991 in Amsterdam, the International Collaborative Group on HNPCC
developed uniform criteria for collaborative studies on HNPCC. (These criteria
were not designed for the diagnosis of HNPCC.) The requirements are:
- The family includes three or more relatives with histologically verified
colorectal cancer, one of whom is a first-degree relative of the other
two, and familial adenomatous polyposis has been excluded.
- The colorectal cancers involve at least two successive generations.
- At least one of the colorectal cancers has been diagnosed before the
age of 50 years.
However, these criteria are restrictive in that they exclude patients
with extra-colonic tumors and late-onset variants, thus overlooking some
HNPCC families by this definition.
The heritable nature of HNPCC (and its variant, the Muir-Torre syndrome)
is caused by germline mutations in one of the several genes involved in
the DNA mismatch repair (MMR) system, an editing mechanism for polymerase
errors that occur during DNA replication.
The MMR genes are so named for their gene products' ability to recognize
and direct repair of nucleotide mispairs and misalignment at short repetitive
se-quences of DNA (called microsatellites) whose length was not accurately
copied during DNA replication. Repair by the MMR system occurs on the newly
synthesized DNA strand, as documented by in vitro repair of mispairs on
the strand containing nicks.[5,6]
Base mispairing can lead to nucleo-tide transitions or transversions,
altering the authentic genetic sequence. If the mismatch occurs in the
coding region for a particular gene, the newly introduced point mutation
may affect the expression and/or function of that particular gene.
Perhaps more importantly, some of the approximately 100,000 DNA micro-satellite
sequences scattered throughout the human genome may be altered in length
when this system is defective. A microsatellite may become lengthened in
a daughter cell if there is nucleotide-pairing slippage (looping) along
the newly synthesized strand during DNA synthesis, or it may become shortened
if the template strand microsatellite has slippage during DNA replication.
This alteration in microsatellite length is termed microsatellite instability
(MIN)[7-9] and can be identified by electrophoretic resolution of amplified
microsatellite DNA sequences. MIN is relatively easy to detect in the laboratory,
and when found in the DNA of a tumor, it indicates the presence of a hypermutable
Occasionally, microsatellites are present in the coding region (exons)
of critical growth regulatory genes. This has been best demonstrated with
the transforming growth factor-beta type II receptor (TGF-beta RII); when
this receptor is bound by TGF-beta in the colonic epithelium, cellular
proliferation is inhibited.
Mutation of TGF-beta RII occurs with defective MMR, commonly resulting
in length changes in the polyadenine mononucleotide repeat microsatellite
(A10) within the gene, producing a frameshift mutation and rendering
the receptor inactive.[10,11] This mutation removes the growth brake provided
by TGF-beta, allowing the colon cells to undergo clonal expansion.
The evolutionarily conserved genes that comprise the MMR system and
that have been found mutated in HNPCC families include hMSH2[12,13], hMLH1[14,15],
hPMS1, and hPMS2. Although other components of the MMR system have
been identified, germline mutations of these components have yet to be
found in HNPCC families.
When a physical deformation remains in the newly replicated DNA double
helix (caused by the mispairing of nucleo-tides or by slippage and looping
at microsatellite loci), a complex termed hMutS-alpha (a heterodimer of
hMSH2 and hMSH6 proteins) identifies the error and binds the DNA at this
Subsequently, hMutS-alpha recruits the hMutL-alpha complex, a heterodimer
of hMLH1 and hPMS2 proteins, which targets the newly synthesized daughter
DNA strand for "long patch" excision repair.
It remains unclear how hPMS1 interacts within the complex. Loss of any
of the four components of the MMR system will inactivate or attenuate repair.
Germline mutations in the hMLH1 and hMSH2 genes account for the majority
(approximately 90%) of HNPCC families identified to date.
One wild-type allele of an MMR gene is generally sufficient to maintain
normal MMR function. For colon cancer to develop in HNPCC patients, a second
somatic event (in addition to the vertically transmitted mutant allele)
must occur in the wild-type allele of a colonocyte. This completely inactivates
both of the MMR genes and causes the hypermutable phenotype seen with
Methods of Diagnosing HNPCC
Identification of genes involved in HNPCC has prompted efforts to diagnose
this condition in presymptomatic patients (see table).
There is no premor-bid clinical phenotype that identifies an HNPCC patient
antecedent to the development of cancer.
Nonneoplastic cells in HNPCC patients have a normal phenotype, since
the inactivation of only one allele of an MMR gene is not permissive of
hypermutability. The presence of inactivating mutations in both alleles
of MMR genes in tumors confirms Knudson's "two-hit" hypothesis
for tumor-suppressor genes.
Although MIN should be a necessary finding for this condition, in fact,
only 92% of HNPCC tumors show MIN. Furthermore, it has been demonstrated
that only a minority of tumors with MIN actually come from HNPCC families.[26,27]
Adenomas in HNPCC patients often manifest MIN,[28,29] indicating that
inactivation of the second allele of an MMR gene occurs as an early event
in colorectal tumorigenesis. Unfortunately, the finding of MIN in a tumor
is not perfectly sensitive and is quite nonspecific, so it is not a practical
screening strategy for HNPCC.
Obtaining peripheral blood is the least invasive method to diagnose
HNPCC. In HNPCC, the lymphocytes will have one mutated allele and one wild-type
allele in one of the above-mentioned MMR genes.
Direct sequencing of the four MMR genes involved in HNPCC is a possible
diagnostic strategy, but the number of genes involved and the number of
exons in each gene make this clinically impractical at this time.
These problems extend to common mutation detection methods like single-stranded
conformational polymorphism (SSCP) and denaturing gradient gel electrophoresis
Nevertheless, direct DNA sequencing of hMLH1 and hMSH2, the two most
common genes involved, is the most reliable approach to diagnosis at this
time. Interpretation of the sequence data, however, may prove difficult,
since the full spectrum of disease-producing mutations and innocuous polymorphisms
has not been catalogued.
The reported mutations in hMLH1 and hMSH2 include insertions, deletions,
nonsense mutations, and some missense mutations.[21,25] Many variations
in the DNA sequences of these genes are not associated with an increased
risk for tumor formation. A large fraction of these mutations yield a truncated
protein after translation, more so with hMSH2 than hMLH1.
This fact has led to the application of an in vitro transcription/translation
assay (IVTT) for these genes. With the IVTT approach, RNA is extracted
from the peripheral blood, reverse transcribed into complementary DNA,
and expressed as protein.
The altered migration of a truncated protein on a polyacrylamide gel
can provide a means of identifying which MMR gene contains an inactivating
mutation. A study assaying hMLH1 and hMSH2 by the IVTT method was about
50% sensitive in patients who fulfilled the Amster-dam criteria for HNPCC.
Linkage analysis can identify current or future family members as carriers
of a mutated MMR gene (and thus distinguishes the carrier as an HNPCC patient).
The mutated allele may be identified from affected family members (and
excluded from unaffected family members) using microsatellites or restriction
fragment length polymorphisms (RFLPs) that are linked to the MMR gene.
This approach, however, requires obtaining blood from more than one generation
of first-degree relatives, including the affected and unaffected members.
The MAMA Technique
Another novel but time-consuming approach for certain mutations missed
by conventional techniques is the isolation of each allele from peripheral
blood lymphocytes into a somatic cell hybrid, termed MAMA (monoallelic
The MAMA method fuses individual chromosomes from human cells from a
patient with an appropriate hamster cell line to individually analyze each
allele for mutations that might be masked by the wild-type allele. However,
the time required to perform this assay makes its use impractical outside
of the research setting.
At this time, the use of the IVTT assay combined with direct DNA sequencing
may be the most appropriate approach for finding germline mutations in
These tests can be applied to families who fit the Amsterdam criteria,
as well as to the young patient (ie, less that 45 years of age) who develops
colon cancer that has characteristics typical of HNPCC tumors (ie, right-sided,
mucinous, poorly differentiated adenocarcinomas).
When available, neoplastic tissue, including paraffin-embedded archival
blocks, can be valuable for MIN analysis, since patients with HNPCC will
usually have microsatellite alterations at multiple loci. Supporting information
at the time of microsatellite analysis includes loss of heterozygosity
of an MMR gene, which can be identified using appropriate microsatellite
The aim of identifying the germline lesion in the patient is for screening
remaining family members. There is no substitute for assessing the family
history, including the ages of affected family members and the occurrence
of extra-colonic tumors.
In clinically defined HNPCC families in which a mutation cannot be identified
by current genetic techniques, or in family members who do not wish to
be genetically tested, a regular screening program consisting of colonoscopy
or barium enema and sigmoidoscopy significantly reduces the rate of tumor
development and death.[32,33]
1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1997. CA Cancer
J Clin 47:5-27, 1997.
2. Boland CR: Hereditary non-polyposis colon cancer (HNPCC), in Scriver
CR, Beaudet AL, Sly WS, et al (eds): Metabolic and Molecular Basis of Inherited
Diseases. New York, NY, McGraw-Hill, Inc., 1997 (in press).
3. Lynch HT, Smyrk TC, Watson P, et al: Genetics, natural history, tumor
spectrum, and pathology of hereditary nonpolyposis colorectal cancer (HNPCC):
An updated review. Gastroenterol 104:1535-1549, 1993.
4. Vasen HFA, Mecklin J-P, Khan PM, et al: The International Collaborative
Group on Hereditary Non-polyposis Colorectal Cancer. Dis Colon Rectum 34:424-425,
5. Holmes J Jr, Clark S, Modrich P: Strand specific mismatch correction
in nuclear extracts of human and drosophila melanogaster cell lines. Proc
Natl Acad Sci USA 87:5837-5841, 1990.
6. Thomas DC, Roberts JD, Kunkel TA: Heteroduplex repair in extracts
of human HeLa cells. J Biol Chem 266:3744-3751, 1990.
7. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer
of the proximal colon. Science 260:816-819, 1993.
8. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations
in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.
Nature 363:558-561, 1993.
9. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis
of familial colorectal cancer. Science 260:812-816, 1993.
10. Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type
II TGF-beta receptor in colon cancer cells with microsatellite instability.
Science 268:1336-1338, 1995.
11. Myeroff LL, Parsons R, Kim S-J, et al: A transforming growth factor
beta receptor type II gene mutation common in colon and gastric but rare
in endometrial cancers with microsatellite instability. Cancer Res 55:5545-5547,
12. Leach FS, Nicolaides NC, Papadopoulos N, et al: Mutations of a mutS
homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225,
13. Fishel R, Lescoe MK, Rao MR, et al: The human mutator gene homolog
MSH2 and its association with hereditary nonpolyposis colon cancer. Cell
14. Papadopoulos N, Nicolaides NC, Wei YF, et al: Mutation of a mutL
homolog in hereditary colon cancer. Science 263:1625-1629, 1994.
15. Bronner CE, Baker SM, Morrison PT, et al: Mutation in the DNA mismatch
repair gene homologue hMLH1 is associated with hereditary non-polyposis
colon cancer (HNPCC). Nature 368:258-261, 1994.
16. Nicolaides NC, Papadopoulos N, Liu B, et al: Mutations of two PMS
homologues in hereditary nonpolyposis colon cancer. Nature 371:75-80, 1994.
17. Drummond JT, Li G-M, Langley MJ, et al: Isolation of an hMSH2-pl60
heterodimer that restores DNA mismatch repair to tumor cells. Science 268:1909,
18. Palombo F, Gallinari P, Iaccarino I, et al: GTBP, a 160-kilodalton
protein essential for mismatch-binding activity in human cells. Science
19. Papadopoulos N, Nicolaides NC, Liu B, et al: Mutations of GTBP in
genetically unstable cells. Science 268:1915-1917, 1995.
20. Fishel R, Ewel A, Lescoe MK: Purified human MSH2 protein binds to
DNA containing mismatched nucleotides. Cancer Res 54:5539-5542, 1994.
21. Marra G, Boland CR: DNA repair and colorectal cancer, in Colorectal
Neoplasia: Part I. The Scientific Basis for Current Management, Gastroenterology
Clinics of North America. Philadelphia, WB Saunders Co, 25(4):755-772,
22. Hemminki A, Peltomaki P, Mecklin J-K: Loss of the wild type MLH1
gene is a feature of hereditary nonpolyposis colorectal cancer. Nature
Genetics 8:405-410, 1994.
23. Williams GT, Geraghty JM, Campbell F, et al: Normal colonic mucosa
in hereditary non-polyposis colorectal cancer (HNPCC) shows no generalized
increase in somatic mutation. Br J Cancer 71:1077-1080, 1995.
24. Knudson AG: Mutation and cancer: Statistical study of retinoblastoma.
Proc Natl Acad Sci USA 68:820-823, 1971.
25. Liu B, Parsons R, Papadopoulos N, et al: Analysis of mismatch repair
genes in hereditary non-polyposis colorectal cancer (HNPCC). Nature Med
26. Brentnall TA, Crispin DA, Bronner MP, et al: Microsatellite instability
in nonneoplastic mucosa from patients with chronic ulcerative colitis.
Cancer Res 56:1237-1240, 1996.
27. Liu B, Farmington SM, Petersen GM, et al: Genetic instability occurs
in the majority of young patients with colorectal cancer. Nature Med 1:348-352,
28. Shibata D, Peinado MA, Ionov Y, et al: Genomic instability in repeated
sequences is an early somatic event in colorectal tumorigenesis that persists
after transformation. Nature Genetics 6:273, 1994.
29. Aaltonen LA, Peltomaki P, Mecklin J-P, et al: Replication errors
in benign and malignant tumors from hereditary nonpolyposis colorectal
cancer patients. Cancer Res 54:1645, 1994.
30. Luce MC, Marra G, Chauhan DP, et al: In vitro transcription/translation
assay for the screening of hMLHI and hMSH2 mutations in familial colon
cancer. Gastroenterol 109:1368, 1995.
31. Papadopoulos N, Leach FS, Kinzler KW, et al: Monoallelic mutation
analysis (MAMA) for identifying germline mutations. Nature Genetics 11:99-102,
32. Sankila R, Aaltonen LA, Jarvinen HJ, et al: Better survival rates
in patients with MLH1-associated hereditary colorectal cancer. Gastroenterol
33. Jarvinen HJ, Mecklin J-P, Sistonen P: Screening reduces colorectal
cancer rate in families with hereditary nonpolyposis colorectal cancer.
Gastroenterol 108:1405-1411, 1995.
This work has been supported by NIH grants DK 02433 and CA 72851,
the Research Service of the Department of Veterans Affairs, and the Johnson